These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 11877357

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K, Dahlöf B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, Gerdts E, Boman K, Bella JN, Devereux RB.
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [Abstract] [Full Text] [Related]

  • 3. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Palmieri V, Okin PM, Bella JN, Wachtell K, Oikarinen L, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB.
    J Hypertens; 2006 Oct; 24(10):2079-84. PubMed ID: 16957569
    [Abstract] [Full Text] [Related]

  • 4. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B.
    J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
    [Abstract] [Full Text] [Related]

  • 5. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint.
    Wachtell K, Smith G, Gerdts E, Dahlöf B, Nieminen MS, Papademetriou V, Bella JN, Ibsen H, Rokkedal J, Devereux RB.
    Am J Cardiol; 2000 Feb 15; 85(4):466-72. PubMed ID: 10728952
    [Abstract] [Full Text] [Related]

  • 6. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 7. Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function.
    Zakynthinos E, Pierutsakos Ch, Konstantinidis K, Zakynthinos S, Papadogiannis D.
    Angiology; 2004 Aug 12; 55(6):669-78. PubMed ID: 15547653
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
    Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahlöf B, Aurigemma GP, Devereux RB.
    Circulation; 2002 Jul 09; 106(2):227-32. PubMed ID: 12105163
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B.
    Hypertension; 2000 Nov 09; 36(5):766-73. PubMed ID: 11082141
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
    Gerdts E, Roman MJ, Palmieri V, Wachtell K, Smith G, Nieminen MS, Dahlöf B, Devereux RB.
    J Hum Hypertens; 2004 Jun 09; 18(6):417-22. PubMed ID: 15103312
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.